Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 112
- Registration Number
- NCT06370715
- Locations
- 🇮🇳
Osmania Medical College & Hospital, Hyderabad, Andhra Pradesh, India
🇮🇳King George Hospital, Visakhapatnam, Visakhapatnam, Andhra Pradesh, India
🇮🇳Diabetes Research Centre, Royapuram, Chennai India, India
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06370728
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22
- Registration Number
- NCT06362265
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia, United States
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT06354660
- Locations
- 🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Tucson Clinical Research Institute, Tucson, Arizona, United States
🇺🇸San Fernando Valley Health Institute, Canoga Park, California, United States
A Study of LY3841136 in Overweight and Obese Participants
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 96
- Registration Number
- NCT06345066
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06342596
- Locations
- 🇬🇧
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 510
- Registration Number
- NCT06338995
- Locations
- 🇯🇵
8-2 Otemachi, Shizuoka, Japan
🇺🇸AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
- Conditions
- Perennial Allergic Rhinitis (PAR)
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT06339008
- Locations
- 🇰🇷
Clinical trial Pharmacy, Seoul, Korea, Republic of
🇵🇱Polimedica PTG Kielce, Kielce, Poland
🇵🇱Centrum Medyczne Promed ul. Olszańska 5G, Krakow, Poland
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 74
- Registration Number
- NCT06313528
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT06297590
- Locations
- 🇺🇸
K2 Medical Research, LLC, Maitland, Florida, United States
🇺🇸Charter Research, LLC, The Villages, Florida, United States
🇺🇸CenExel iResearch, LLC (CenExel iRA), Decatur, Georgia, United States